Papers
3
Total Citations
141
H-Index
3
About
Heather Lin is a leading clinical researcher in thoracic surgical oncology, with a focused expertise in neoadjuvant immunotherapy for non–small cell lung cancer (NSCLC). Her major contributions center on evaluating the surgical safety and feasibility of combining immune checkpoint inhibitors—specifically nivolumab and ipilimumab—prior to tumor resection. As a key investigator in the landmark NEOSTAR study, Dr. Lin’s work has provided critical evidence that these neoadjuvant regimens do not compromise surgical outcomes, while potentially improving pathologic responses. Her most cited paper (2022, 94 citations) rigorously analyzed perioperative complications and resection rates, establishing a foundation for integrating immunotherapy into standard surgical pathways. Her subsequent 2023 study extended this analysis to include chemotherapy combinations, further refining risk stratification. With a cumulative citation impact exceeding 140, Dr. Lin’s research bridges the gap between medical oncology and surgery, directly informing clinical decision-making for patients with resectable NSCLC. Her findings are widely referenced in guidelines and have shaped the design of ongoing phase III trials, cementing her role as a pivotal voice in the era of immuno-surgical treatment for lung cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3